Sana reports Q3 2026 progress on SC451 and SG293, NEJM data on UP421
Sana said it continues moving toward starting trials for two cell therapy candidates while reporting $121.7 million in cash as of September 30, 2026.
SEC filing
7 stories
Sana said it continues moving toward starting trials for two cell therapy candidates while reporting $121.7 million in cash as of September 30, 2026.
SEC filing
Third-quarter 2026 update details REC-4881 polyp reductions in FAP, early REC-1245 responses, a Sanofi development-candidate option, and cash runway extended into 2029.
SEC filing
The company priced a 61.5 million share offering at $3.25 as Sanofi exercised an option on a first collaboration candidate and new REC-4881 and REC-1245 trial data emerged.
SEC filing (4)